Rare mutations in the PIK3CA gene contribute to aggressive endometrial cancer

DNA and Cell Biology

Volumn 29, Issue 2, 2010, Pages 65-70

  Konstantinova, Darina ^a   Kaneva, Radka ^a   Dimitrov, Roumen ^b   Savov, Alexey ^b   Ivanov, Stephan ^c   Dyankova, Tzvetanka ^c   Kremensky, Ivo ^a,b   Mitev, Vanio ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b University Hospital of Obstetrics and Gynecology 'Maichin Dom' Bulgaria   (Bulgaria)

^c National Oncology Center Bulgaria   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ENDOMETRIUM CANCER; EXON; FEMALE; GENE; GENE ACTIVATION; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; ONCOGENE K RAS; PIK3CA GENE; PRIORITY JOURNAL; TUMOR DIFFERENTIATION; WILD TYPE;

EID: 84879192085     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2009.0939     Document Type: Article

References (31)

1. Bader, A.G., Kang, S., and Vogt, P.K. (2006). Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 103, 1475-1479.
2. Caduff, R.F., Johnston, C.M., and Frank, T.S. (1995). Mutations of the Ki-ras oncogene in carcinoma of the endometrium. Am J Pathol 146, 182-188.
3. Campbell, I.G., Russell, S.E., Choong, D.Y., Montgomery, K.G., Ciavarella, M.L., Hooi, C.S., Cristiano, B.E., Pearson, R.B., and Phillips, W.A. (2004). Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64, 7678-7681.
4. Cantley, L.C. (2002). The phosphoinositide 3-kinase pathway. Science 296, 1655-1657.
5. Carson, J.D., Van Aller, G., Lehr, R., Sinnamon, R.H., Kirkpatrick, R.B., Auger, K.R., Dhanak, D., Copeland, R.A., Gontarek, R.R., Tummino, P.J., and Luo, L. (2008). Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. Biochem J 409, 519-524.
6. Catasus, L., Gallardo, A., Cuatrecasas, M., and Prat, J. (2008). PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod Pathol 21, 131-139.
7. Esteller, M., Garcia, A., Martinez-Palones, J.M., Xercavins, J., and Reventos, J. (1997). The clinicopathological significance of K-RAS point mutation and gene amplification in endometrial cancer. Eur J Cancer 33, 1572-1577.
8. Gustin, J.P., Karakas, B., Weiss, M.B., Abukhdeir, A.M., Lauring, J., Garay, J.P., Cosgrove, D., Tamaki, A., Konishi, H., Konishi, Y., Mohseni, M., Wang, G., Rosen, D.M., Denmeade, S.R., Higgins, M.J., Vitolo, M.I., Bachman, K.E., and Park, B.H. (2009). Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci USA 106, 2835-2840.
9. Gymnopoulos, M., Elsliger, M.A., and Vogt, P.K. (2007). Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA 104, 5569-5574.
10. Hayes, M.P., Douglas, W., and Ellenson, L.H. (2009). Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. Gynecol Oncol 113, 370-373.
11. Hayes, M.P., Wang, H., Espinal-Witter, R., Douglas, W., Solomon, G.J., Baker, S.J., and Ellenson, L.H. (2006). PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 12(20 Pt 1), 5932-5935.
12. Hutchinson, J., Jin, J., Cardiff, R.D., Woodgett, J.R., and Muller, W.J. (2001). Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 21, 2203-2212.
13. Ikenoue, T., Kanai, F., Hikiba, Y., Obata, T., Tanaka, Y., Imamura, J., Ohta, M., Jazag, A., Guleng, B., Tateishi, K., Asaoka, Y., Matsumura, M., Kawabe, T., and Omata, M. (2005). Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 65, 4562-4567.
14. Isakoff, S.J., Engelman, J.A., Irie, H.Y., Luo, J., Brachmann, S.M., Pearline, R.V., Cantley, L.C., and Brugge, J.S. (2005). Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65, 10992-11000.
15. Kang, S., Bader, A.G., and Vogt, P.K. (2005). Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 102, 802-807.
16. Kang, S., Seo, S.S., Chang, H.J., Yoo, C.W., Park, S.Y., and Dong, S.M. (2008). Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma. Int J Gynecol Cancer 18, 1339-1343.
17. Miyake, T., Yoshino, K., Enomoto, T., Takata, T., Ugaki, H., Kim, A., Fujiwara, K., Miyatake, T., Fujita, M., and Kimura, T. (2008). PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences. Cancer Lett 261, 120-126.
18. Mori, N., Kyo, S., Sakaguchi, J., Mizumoto, Y., Ohno, S., Maida, Y., Hashimoto, M., Takakura, M., and Inoue, M. (2007). Concomitant activation of AKT with extracellular-regulated kinase 1=2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosiss. Cancer Sci 98, 1881-1888.
19. Nakayama, K., Nakayama, N., Kurman, R.J., Cope, L., Pohl, G., Samuels, Y., Velculescu, V.E., Wang, T.L., and Shih Ie, M. (2006). Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther 5, 779-785.
20. Oda, K., Okada, J., Timmerman, L., Rodriguez-Viciana, P., Stokoe, D., Shoji, K., Taketani, Y., Kuramoto, H., Knight, Z.A., Shokat, K.M., and McCormick, F. (2008). PIK3CA cooperates with other phosphatidylinositol 30-kinase pathway mutations to effect oncogenic transformation. Cancer Res 68, 8127-8136.
21. Ollikainen, M., Gylling, A., Puputti, M., Nupponen, N.N., Abdel-Rahman, W.M., Butzow, R., and Peltomaki, P. (2007). Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. Int J Cancer 121, 915-920.
22. Pappa, K.I., Choleza, M., Markaki, S., Giannikaki, E., Kyroudi, A., Vlachos, G., Voulgaris, Z., and Anagnou,N.P. (2006). Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status. Gynecol Oncol 100, 596-600.
23. Qiao, M., Sheng, S., and Pardee, A.B. (2008). Metastasis and AKT activation. Cell Cycle 7, 2991-2996.
24. Rodriguez-Viciana, P., Marte, B.M., Warne, P.H., and Downward, J. (1996). Phosphatidylinositol 30 kinase: one of the effectors of Ras. Philos Trans R Soc Lond 351, 225-231; discussion 231-1222
25. Salvesen, H.B., Carter, S.L., Mannelqvist, M., Dutt, A., Getz, G., Stefansson, I.M., Raeder, M.B., Sos, M.L., Engelsen, I.B., Trovik, J., Wik, E., Greulich, H., Bo, T.H., Jonassen, I., Thomas, R.K., Zander, T., Garraway, L.A., Oyan, A.M., Sellers, W.R., Kalland, K.H., Meyerson, M., Akslen, L.A., and Beroukhim, R. (2009). Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci USA.
26. Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S.M., Riggins, G.J., Willson, J.K., Markowitz, S., Kinzler, K.W., Vogelstein, B., and Velculescu, V.E. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554. (Pubitemid 38541907)
27. Toulany, M., Baumann, M., and Rodemann, H.P. (2007). Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity. Mol Cancer Res 5, 863-872.
28. Tsuda, H., Jiko, K., Yajima, M., Yamada, T., Tanemura, K., Tsunematsu, R., Ohmi, K., Sonoda, T., and Hirohashi, S. (1995). Frequent occurrence of c-Ki-ras gene mutations in well differentiated endometrial adenocarcinoma showing infiltrative local growth with fibrosing stromal response. Int J Gynecol Pathol 14, 255-259.
29. Velasco, A., Bussaglia, E., Pallares, J., Dolcet, X., Llobet, D., Encinas, M., Llecha, N., Palacios, J., Prat, J., and Matias-Guiu, X. (2006). PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. Hum Pathol 37, 1465-1472.
30. Willner, J., Wurz, K., Allison, K.H., Galic, V., Garcia, R.L., Goff, B.A., and Swisher, E.M. (2007). Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum Pathol 38, 607-613.
31. Zhao, L., and Vogt, P.K. (2008). Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA 105, 2652-2657.